Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.30 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901137 | 0.79 | RPS6KA5 (0.34) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL16125086 | 0.76 | ALDH1A1 (0.38) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901135 | 0.72 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL16125091 | 0.70 | PDGFRB (0.46) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL1999094 | 0.67 | MAPT (0.53) | CHEK1 | |
| SCHEMBL1993575 | 0.67 | PIK3CG (0.34) | HPGDS | |
| SCHEMBL20305881 | 0.66 | ALDH1A1 (0.33) | — | |
| SCHEMBL29712713 | 0.66 | NQO1 (0.41) | SOS2HPGDSNQO1 | |
| SCHEMBL23705849 | 0.66 | NQO1 (0.34) | SOS2NQO1 | |
| SCHEMBL30097006 | 0.66 | NQO1 (0.34) | SOS2NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | SOS2 4158/4885MAPK1 2681/4885PIK3CA 580/4885 |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR2, FGFR4 | SOS2 1507/4885MAPK1 322/4885PIK3CA 83/4885 |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | SOS2 1163/4885MAPK1 333/4885PIK3CA 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.